Disease · MONDO_0001409
Trials13
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
1 to 13 of 13
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01952847 | Randomized Trial of Glutamine in Patients With Mucositis or Esophagitis | Phase 3 | 77 | 2022-06-15 | Advanced Cancers | GLUTAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT00280150 | Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | Phase 1/2 | 46 | 2017-06-19 | Lung Cancer | BEVACIZUMAB, CARBOPLATIN, ERLOTINIB HYDROCHLORIDE, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT04225026 | Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer | Phase 2 | 39 | 2023-03-23 | Esophagitis | AVASOPASEM MANGANESE | Its record names the disease | ClinicalTrials.gov |
| NCT01132638 | Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease | Phase 3 | 713 | GERD | ESOMEPRAZOLE, PANTOPRAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT02860624 | Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients | Phase 3 | 550 | Gastroesophageal Reflux Disease | ESOMEPRAZOLE, ILAPRAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT06953986 | A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks | Not applicable | 414 | GERD | ESOMEPRAZOLE, VONOPRAZAN | Its record names the disease | ClinicalTrials.gov | |
| NCT01400945 | Efficacy Study of AGSPT201 Tablet to Treat Gastroesophageal Reflux Disease | Phase 3 | 154 | Gastroesophageal Reflux Disease | PANTOPRAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT02577393 | Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy | Phase 2 | 83 | Lung Neoplasms, Esophagitis, Prevention & Control, Epigallocatechin Gallate | EPIGALOCATECHIN GALLATE | Its record names the disease | ClinicalTrials.gov | |
| NCT00006012 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer | Phase 1/2 | 73 | Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity | AMIFOSTINE, CISPLATIN, ETOPOSIDE, FILGRASTIM, PACLITAXEL, TOPOTECAN HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT01657578 | Optimal Dosing of Omeprazole in Neonates | Phase 2 | 55 | Gastroesophageal Reflux Disease (GERD) | OMEPRAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT01336530 | Tepilta® Versus Oxetacaine, Antacids and Placebo | Phase 3 | 40 | Radiation-induced Oesophagitis | ALUMINUM HYDROXIDE, MAGNESIUM HYDROXIDE, OXETHAZAINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00216788 | The Effect of Nexium on Transmucosal Esophageal Leak | Phase 1 | 35 | Reflux, Esophagitis, Barrett's Esophagus | ESOMEPRAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT00624546 | Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD | 24 | GERD, Gastroesophageal Reflux | ESOMEPRAZOLE | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001409/trials